Plasminogen activator inhibitor-1 4G/5G polymorphism and retinopathy risk in type 2 diabetes: A meta-analysis

BMC Medicine

Volumn 11, Issue 1, 2013, Pages

  Zhang, Tengyue ^a,b   Pang, Chong ^c   Li, Ningdong ^a   Zhou, Elaine ^d   Zhao, Kanxing ^a  

^a TIANJIN MEDICAL UNIVERSITY   (China)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c KEY LABORATORY OF CANCER PREVENTION AND THERAPY   (China)

^d YALE UNIVERSITY   (United States)

Author keywords

Diabetic retinopathy; Meta analysis; PAI 1; Polymorphism; Type 2 diabetes

Indexed keywords

PLASMINOGEN ACTIVATOR INHIBITOR 1;

ALLELE; ARTICLE; CAUCASIAN; COMPUTER PROGRAM; DIABETIC RETINOPATHY; DISEASE DURATION; DISEASE PREDISPOSITION; DNA POLYMORPHISM; ETHNICITY; GENETIC ASSOCIATION; GENOTYPE; HUMAN; META ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; SYSTEMATIC REVIEW;

DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; DIABETIC RETINOPATHY; ETHNIC GROUPS; HUMANS; PLASMINOGEN ACTIVATOR INHIBITOR 1; POLYMORPHISM, GENETIC; RISK ASSESSMENT;

EID: 84871689989     PISSN: None     EISSN: 17417015     Source Type: Journal    
DOI: 10.1186/1741-7015-11-1     Document Type: Article

References (44)

1. Hallman DM, Huber JC, Gonzalez VH, Klein BE, Klein R, Hanis CL. Familial aggregation of severity of diabetic retinopathy in Mexican Americans from Starr County, Texas. Diabetes Care 2005, 28:1163-1168. 10.2337/diacare.28.5.1163, 15855583.
2. Uhlmann K, Kovacs P, Boettcher Y, Hammes HP, Paschke R. Genetics of diabetic retinopathy. Exp Clin Endocrinol Diabetes 2006, 114:275-294. 10.1055/s-2006-924260, 16868886.
3. Cilensek I, Mankoc S, Globocnik-Petrovic M, Petrovic D. The 4a/4a genotype of the VNTR polymorphism for endothelial nitric oxide synthase (eNOS) gene predicts risk for proliferative diabetic retinopathy in Slovenian patients (Caucasians) with type 2 diabetes mellitus. Mol Biol Rep 2012, 39:7061-7067. 10.1007/s11033-012-1537-8, 22311033.
4. Petrovic MG, Cilensek I, Petrovic D. Manganese superoxide dismutase gene polymorphism (V16A) is associated with diabetic retinopathy in Slovene (Caucasians) type 2 diabetes patients. Dis Markers 2008, 24:59-64.
5. Churchill AJ, Carter JG, Ramsden C, Turner SJ, Yeung A, Brenchley PE, Ray DW. VEGF polymorphisms are associated with severity of diabetic retinopathy. Invest Ophthalmol Vis Sci 2008, 49:3611-3616. 10.1167/iovs.07-1383, 18441306.
6. Hudson BI, Stickland MH, Futers TS, Grant PJ. Effects of novel polymorphisms in the RAGE gene on transcriptional regulation and their association with diabetic retinopathy. Diabetes 2001, 50:1505-1511. 10.2337/diabetes.50.6.1505, 11375354.
7. Richeti F, Noronha RM, Waetge RT, de Vasconcellos JP, de Souza OF, Kneipp B, Assis N, Rocha MN, Calliari LE, Longui CA, Monte O, de Melo MB. Evaluation of AC(n) and C(-106)T polymorphisms of the aldose reductase gene in Brazilian patients with DM1 and susceptibility to diabetic retinopathy. Mol Vis 2007, 13:740-745. 2765471, 17563730.
8. Maeda M, Yamamoto I, Fukuda M, Nishida M, Fujitsu J, Nonen S, Igarashi T, Motomura T, Inaba M, Fujio Y, Azuma J. MTHFR gene polymorphism as a risk factor for diabetic retinopathy in type 2 diabetic patients without serum creatinine elevation. Diabetes Care 2003, 26:547-548. 10.2337/diacare.26.2.547, 12547904.
9. Sobrin L, Green T, Sim X, Jensen RA, Tai ES, Tay WT, Wang JJ, Mitchell P, Sandholm N, Liu Y, Hietala K, Iyengar SK, Brooks M, Buraczynska M, van Zuydam N, Smith AV, Gudnason V, Doney AS, Morris AD, Leese GP, Palmer CN, Swaroop A, Taylor HA, Wilson JG, Penman A, Chen CJ, Groop PH, Saw SM, Aung T, Klein BE, et al. Candidate gene association study for diabetic retinopathy in persons with type 2 diabetes: the Candidate gene Association Resource (CARe). Invest Ophthalmol Vis Sci 2011, 52:7593-7602. 10.1167/iovs.11-7510, 3183981, 21873659.
10. Grant MB, Spoerri PE, Player DW, Bush DM, Ellis EA, Caballero S, Robison WG. Plasminogen activator inhibitor (PAI)-1 overexpression in retinal microvessels of PAI-1 transgenic mice. Invest Ophthalmol Vis Sci 2000, 41:2296-2302.
11. Margaglione M, Cappucci G, d'Addedda M, Colaizzo D, Giuliani N, Vecchione G, Mascolo G, Grandone E, Di Minno G. PAI-1 plasma levels in a general population without clinical evidence of atherosclerosis: relation to environmental and genetic determinants. Arterioscler Thromb Vasc Biol 1998, 18:562-567. 10.1161/01.ATV.18.4.562, 9555861.
12. Ashton N. Vascular basement membrane changes in diabetic retinopathy. Montgomery lecture, 1973. Br J Ophthalmol 1974, 58:344-366. 10.1136/bjo.58.4.344, 1214780, 4138036.
13. Henry M, Tregouet DA, Alessi MC, Aillaud MF, Visvikis S, Siest G, Tiret L, Juhan-Vague I. Metabolic determinants are much more important than genetic polymorphisms in determining the PAI-1 activity and antigen plasma concentrations: a family study with part of the Stanislas Cohort. Arterioscler Thromb Vasc Biol 1998, 18:84-91. 10.1161/01.ATV.18.1.84, 9445260.
14. Stegnar M, Uhrin P, Peternel P, Mavri A, Salobir-Pajnic B, Stare J, Binder BR. The 4G/5G sequence polymorphism in the promoter of plasminogen activator inhibitor-1 (PAI-1) gene: relationship to plasma PAI-1 level in venous thromboembolism. Thromb Haemost 1998, 79:975-979.
15. Eriksson P, Kallin B, Van't Hooft FM, Bavenholm P, Hamsten A. Allele-specific increase in basal transcription of the plasminogen-activator inhibitor 1 gene is associated with myocardial infarction. Proc Natl Acad Sci USA 1995, 92:1851-1855. 10.1073/pnas.92.6.1851, 42380, 7892190.
16. Santos KG, Tschiedel B, Schneider J, Souto K, Roisenberg I. Diabetic retinopathy in Euro-Brazilian type 2 diabetic patients: relationship with polymorphisms in the aldose reductase, the plasminogen activator inhibitor-1 and the methylenetetrahydrofolate reductase genes. Diabetes Res Clin Pract 2003, 61:133-136. 10.1016/S0168-8227(03)00112-8, 12951282.
17. Ezzidi I, Mtiraoui N, Chaieb M, Kacem M, Mahjoub T, Almawi WY. Diabetic retinopathy, PAI-1 4G/5G and -844G/A polymorphisms, and changes in circulating PAI-1 levels in Tunisian type 2 diabetes patients. Diabetes Metab 2009, 35:214-219. 10.1016/j.diabet.2008.12.002, 19419896.
18. Globocnik-Petrovic M, Hawlina M, Peterlin B, Petrovic D. Insertion/deletion plasminogen activator inhibitor 1 and insertion/deletion angiotensin-converting enzyme gene polymorphisms in diabetic retinopathy in type 2 diabetes. Ophthalmologica 2003, 217:219-224. 10.1159/000068975, 12660488.
19. Nagi DK, McCormack LJ, Mohamed-Ali V, Yudkin JS, Knowler WC, Grant PJ. Diabetic retinopathy, promoter (4G/5G) polymorphism of PAI-1 gene, and PAI-1 activity in Pima Indians with type 2 diabetes. Diabetes Care 1997, 20:1304-1309. 10.2337/diacare.20.8.1304, 9250459.
20. Zietz B, Buechler C, Drobnik W, Herfarth H, Scholmerich J, Schaffler A. Allelic frequency of the PAI-1 4G/5G promoter polymorphism in patients with type 2 diabetes mellitus and lack of association with PAI-1 plasma levels. Endocr Res 2004, 30:443-453. 10.1081/ERC-200035728, 15554360.
21. Broch M, Gutierrez C, Aguilar C, Simon I, Richart C, Vendrell J. Genetic variation in promoter (4G/5G) of plasminogen activator inhibitor 1 gene in type 2 diabetes. Absence of relationship with microangiopathy. Diabetes Care 1998, 21:463.
22. Murata M, Maruyama T, Suzuki Y, Saruta T, Ikeda Y. Paraoxonase 1 Gln/Arg polymorphism is associated with the risk of microangiopathy in Type 2 diabetes mellitus. Diabet Med 2004, 21:837-844. 10.1111/j.1464-5491.2004.01252.x, 15270786.
23. Wong TY, Poon P, Szeto CC, Chan JC, Li PK. Association of plasminogen activator inhibitor-1 4G/4G genotype and type 2 diabetic nephropathy in Chinese patients. Kidney Int 2000, 57:632-638. 10.1046/j.1523-1755.2000.00884.x, 10652041.
24. Liu SQ, Xue YM, Yang GC, He FY, Zhao XS. Relationship between plasminogen activator inhibitor-1 gene 4G/5G polymorphism and type 2 diabetic nephropathy in Chinese Han patients in Guangdong Province. Di Yi Jun Yi Da Xue Xue Bao 2004, 24:904-907.
25. Lau J, Ioannidis JP, Schmid CH. Quantitative synthesis in systematic reviews. Ann Intern Med 1997, 127:820-826.
26. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986, 7:177-188. 10.1016/0197-2456(86)90046-2, 3802833.
27. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959, 22:719-748.
28. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994, 50:1088-1101. 10.2307/2533446, 7786990.
29. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997, 315:629-634. 10.1136/bmj.315.7109.629, 2127453, 9310563.
30. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 2009, 339:b2535. 10.1136/bmj.b2535, 2714657, 19622551.
31. Fu YP, Hallman DM, Gonzalez VH, Klein BE, Klein R, Hayes MG, Cox NJ, Bell GI, Hanis CL. Identification of diabetic retinopathy genes through a genome-wide association study among Mexican-Americans from Starr County, Texas. J Ophthalmol 2010, 2010:861291. 2939442, 20871662.
32. Huang YC, Lin JM, Lin HJ, Chen CC, Chen SY, Tsai CH, Tsai FJ. Genome-wide association study of diabetic retinopathy in a Taiwanese population. Ophthalmology 2011, 118:642-648. 10.1016/j.ophtha.2010.07.020, 21310492.
33. Liew G, Klein R, Wong TY. The role of genetics in susceptibility to diabetic retinopathy. Int Ophthalmol Clin 2009, 49:35-52.
34. Niu W, Qi Y. An updated meta-analysis of methylenetetrahydrofolate reductase gene 677C/T polymorphism with diabetic nephropathy and diabetic retinopathy. Diabetes Res Clin Pract 2012, 95:110-118. 10.1016/j.diabres.2011.10.009, 22056717.
35. Zintzaras E, Chatzoulis DZ, Karabatsas CH, Stefanidis I. The relationship between C677T methylenetetrahydrofolate reductase gene polymorphism and retinopathy in type 2 diabetes: a meta-analysis. J Hum Genet 2005, 50:267-275. 10.1007/s10038-005-0250-z, 15902512.
36. Zhou JB, Yang JK. Angiotensin-converting enzyme gene polymorphism is associated with proliferative diabetic retinopathy: a meta-analysis. Acta Diabetol 2010, 47:187-193.
37. Fujisawa T, Ikegami H, Kawaguchi Y, Hamada Y, Ueda H, Shintani M, Fukuda M, Ogihara T. Meta-analysis of association of insertion/deletion polymorphism of angiotensin I-converting enzyme gene with diabetic nephropathy and retinopathy. Diabetologia 1998, 41:47-53. 10.1007/s001250050865, 9498629.
38. Wiwanitkit V. Angiotensin-converting enzyme gene polymorphism is correlated to diabetic retinopathy: a meta-analysis. J Diabetes Complications 2008, 22:144-146. 10.1016/j.jdiacomp.2006.09.004, 18280446.
39. Zhao T, Zhao J. Association between the -634C/G polymorphisms of the vascular endothelial growth factor and retinopathy in type 2 diabetes: a meta-analysis. Diabetes Res Clin Pract 2010, 90:45-53. 10.1016/j.diabres.2010.05.029, 20591524.
40. Knowler WC, Bennett PH, Bottazzo GF, Doniach D. Islet cell antibodies and diabetes mellitus in Pima Indians. Diabetologia 1979, 17:161-164. 10.1007/BF01219743, 389722.
41. Knowler WC, Bennett PH, Hamman RF, Miller M. Diabetes incidence and prevalence in Pima Indians: a 19-fold greater incidence than in Rochester, Minnesota. Am J Epidemiol 1978, 108:497-505.
42. Hirschhorn JN, Lohmueller K, Byrne E, Hirschhorn K. A comprehensive review of genetic association studies. Genet Med 2002, 4:45-61. 10.1097/00125817-200203000-00002, 11882781.
43. Schadt EE. Molecular networks as sensors and drivers of common human diseases. Nature 2009, 461:218-223. 10.1038/nature08454, 19741703.
44. Ioannidis JP, Trikalinos TA, Ntzani EE, Contopoulos-Ioannidis DG. Genetic associations in large versus small studies: an empirical assessment. Lancet 2003, 361:567-571. 10.1016/S0140-6736(03)12516-0, 12598142.